Vetbiobank is a veterinary french biotech specialized since 2011 in the development and manufacturing of innovative animal cell-based drugs for treating chronic inflammatory diseases. Its mission is to promote animal well-being through biological products with high safety profile, long term efficacy and low owner’s constraints.
Vetbiobank sets up in Lyon (France) a pharmaceutical facility for industrial biomanufacturing of clinical grade-neonatal mesenchymal stem cells, developed by its R&D site, leveraging its proprietary and fully integrated process.
Its most advanced product addresses the € 1,9 Bn worth canine osteoarthritis market. It enters the last clinical development stage, in the context of an exclusive outlicensing partnership for distribution after EMA market authorization. Pipeline includes other developments such as in canine atopic dermatitis and feline gingivostomatitis.